-
-
- R&D Unit
- Industrial Vaccine Production Unit
- Vaccine and Immunization Training Unit
- Vaccine Epidemiology Unit
- Preclinical and Clinical Research and Project Coordination Unit
- Epidemiology of Pandemic-Risk Infectious Agents Unit
- Bioterrorism Unit
- Laboratory Animal Production/Testing and Preclinical Research Unit
- Tissue Culture Collection, Viral and Bacterial Culture Banking Unit
- Quality Control Laboratory Unit
- Training, Administrative, and Financial Services Unit
-
-
-
- Announcements
- Key Dates
- FAQ
- Contact
Evaluation of Adverse Effects Reported by Participants Following the Administration of Two Doses of TURKOVAC Vaccine via a Telephone Survey Study
TURKOVAC vaccine is a COVID-19 vaccine developed, produced, and licensed in Türkiye, which is inactive, meaning it contains an inactivated virus that does not cause disease but generates an immune response.
Evaluation of Adverse Effects Reported by Participants Following One Dose of TURKOVAC Vaccine via a Telephone Survey Study
TURKOVAC vaccine is a COVID-19 vaccine developed, produced, and licensed in Türkiye, which is inactive, meaning it contains an inactivated virus that does not cause disease but generates an immune response.
Evaluation of Self-Reported Allergic Adverse Events Following the Administration of TURKOVAC Vaccine Among the General Group and Individuals with a History of Allergy
TURKOVAC vaccine is a COVID-19 vaccine developed, produced, and licensed in Türkiye, which is inactive, meaning it contains an inactivated virus that does not cause disease but generates an immune response.